Cancer Research

Ivan Kairatov is a seasoned figure in the biopharmaceutical landscape, recognized for his deep-seated expertise in the intersection of nanotechnology and therapeutic innovation. With a career rooted in the rigorous environment of research and development, Kairatov has spent years navigating the

The recent awarding of the European Research Council Advanced Grant to Christoph Bock represents a pivotal shift in the trajectory of modern oncology by prioritizing the development of sophisticated living drugs. These therapies, particularly chimeric antigen receptor (CAR) T cells, have already

Pancreatic cancer has remained an almost invincible adversary in the medical world, frequently defying the very treatments that have successfully tamed other aggressive forms of the disease. While oncology has celebrated remarkable progress in targeted therapies, pancreatic ductal adenocarcinoma

The landscape of oncology is often defined by the tension between early intervention and the risk of over-treatment, a dilemma nowhere more apparent than in prostate cancer screening. For decades, the medical community has relied on the Prostate-Specific Antigen (PSA) test, a tool that, while

While significant progress has been made in the treatment of many childhood illnesses, pediatric bone cancer continues to present a formidable obstacle for oncologists and researchers alike. Dr. Theodore Scott Nowicki, a prominent researcher at UCLA, was recently recognized for his innovative

The medical community is navigating a period where surviving a terminal diagnosis no longer guarantees a life free from severe physiological repercussions due to the unintended consequences of high-potency treatments. Oncology has entered a golden age of precision medicine and immunotherapy, yet